A Phase 2 interventional study of TR701 FA in Major Cutaneous Abscess, Cellulitis and Erysipelas, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.
Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cellulitis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cellulitis · United States.
Among the 75 studies in Cellulitis with a site in United States, this one is the 30th largest by enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2012, is one of 14 in phase 2, and was the 40th registered.
160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.
Browse Cellulitis studies →1 of the 75 studies in Cellulitis with a site in United States is open now. Recruiting first, the newest first:
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Cellulitis studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 157 across 124 interventional studies indexed under Cellulitis.
Median enrollment 153 across the 65 interventional studies, 416 across the 7 observational. Of the 72 that completed or were terminated, 38 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.
Merck & Co., Inc has 2 studies filed under Cellulitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Cellulitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 75 studies in Cellulitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: TR701 FA
1 tablet 200 mg once daily
Also known as: Tedizolid
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).
Time frame: 24-31 days
| Milestone | TR-701 FA |
|---|---|
| Started | 200 |
| Completed | 186 |
| Not completed | 14 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Physician decision | 1 |
Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).
| participants | TR-701 FA |
|---|---|
| Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | 91 |
Collected over From the Informed Consent Form signature through the late follow-up visit, up to 32 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TR-701 FA | — | 2/200 (1%) | 58/200 (29%) |
| Event | TR-701 FA |
|---|---|
| hemoptysisRespiratory, thoracic and mediastinal disorders | 1/200 |
| thrombophlebitis septicInfections and infestations | 1/200 |
| Event | TR-701 FA |
|---|---|
| NauseaGastrointestinal disorders | 22/200 |
| diarrheaGastrointestinal disorders | 13/200 |
| cellulitisInfections and infestations | 10/200 |
| abscessInfections and infestations | 9/200 |
| vomitingGastrointestinal disorders | 9/200 |
| dizzinessNervous system disorders | 7/200 |
| headacheNervous system disorders | 7/200 |
| chillsGeneral disorders | 4/200 |
| constipationGastrointestinal disorders | 4/200 |
| somnolenceNervous system disorders | 4/200 |
| Age, Continuous(years) | TR-701 FA |
|---|---|
| Mean | 39.5 ± 13.04 |
| Sex: Female, Male(Participants) | TR-701 FA |
|---|---|
| Female | 71 |
| Male | 129 |
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2012 to primary completion in Aug 2012, 6 months.
Results were first posted in Mar 2015, 2 years 6 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →